Thyrocare Technologies Limited
NSE: THYROCAREMarket Closed • NSE
Day range
52 week range
Thyrocare Technologies Limited closed at INR485.25 (-0.47%) on volume 0.76x its 20-day average, trading 26.7% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved +4.1% QoQ
2026-06-23
DIVIDEND Announced
Dividend - Rs 7 Per Share
2025-11-28
BONUS Announced
Bonus 2:1
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Strong Capital Efficiency: ROCE stands at 35.4%
Low Debt Profile: Debt-to-Equity is comfortable at 0.09x
High Cash Flow Conversion: CFO/PAT averaged 1.45x over last 3 years
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Diagnostics & Research.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 23 Jun 2026 | Dividend | ₹7.00 / share | — | 23 Jun 2026 |
| 28 Nov 2025 | Bonus issue | 2:1 bonus ratio | — | 28 Nov 2025 |
| 24 Oct 2025 | Dividend | ₹7.00 / share | — | 24 Oct 2025 |
| 25 Jul 2025 | Dividend | ₹21.00 / share | — | 25 Jul 2025 |
| 16 Aug 2024 | Dividend | ₹18.00 / share | — | 16 Aug 2024 |
| 20 Apr 2023 | Dividend | ₹18.00 / share | — | 20 Apr 2023 |
| — | Annual General Meeting | Annual General Meeting | — | 25 Jul 2022 |
| 12 May 2022 | Dividend | ₹15.00 / share | — | 11 May 2022 |
| — | Dividend | ₹15.00 / share | — | 17 Jun 2021 |
| 13 Nov 2020 | Dividend | ₹10.00 / share | — | 12 Nov 2020 |
| 22 Nov 2019 | Dividend | ₹5.00 / share | — | 21 Nov 2019 |
| — | Dividend | ₹20.00 / share | — | 14 Aug 2019 |
| — | Dividend | ₹5.00 / share | — | 02 Aug 2018 |
| 16 Feb 2018 | Dividend | ₹5.00 / share | — | 15 Feb 2018 |
| — | Dividend | ₹5.00 / share | — | 03 Aug 2017 |
| 09 Feb 2017 | Dividend | ₹5.00 / share | — | 08 Feb 2017 |
| — | Dividend | ₹2.50 / share | — | 01 Sept 2016 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.
IndiaHealthcare
Is Thyrocare Technologies Limited Shariah compliant?
Thyrocare Technologies Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.66%) complies with AAOIFI threshold (≤ 33%).
What is Thyrocare Technologies Limited's current valuation relative to peers?
Thyrocare Technologies Limited trades at a P/E of 44.0x compared to the sector median of 37x, and a Price-to-Book of 13.2x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.09x. Interest coverage is 73.1x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 7.7% while net profit growth averaged 18.2%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.